Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N6U8

UPID:
GP161_HUMAN

ALTERNATIVE NAMES:
G-protein coupled receptor RE2

ALTERNATIVE UPACC:
Q8N6U8; B3KV34; B7Z5D7; B7Z5E8; B7Z5Z6; F5GXD6; F5H6J7; O75963; Q5TGK0; Q5TGK1; Q5TGK2

BACKGROUND:
The G-protein coupled receptor 161, alternatively known as GPR161, acts as a key inhibitor in the Shh signaling pathway by promoting GLI3's processing into its repressor form, GLI3R, during neural development. Its regulation of cAMP levels in primary cilia and recycling endosomes is vital for controlling Shh signaling, highlighting its importance in embryonic neural tube formation.

THERAPEUTIC SIGNIFICANCE:
GPR161's malfunction is linked to the development of Medulloblastoma, an aggressive brain cancer predominantly affecting children. The exploration of GPR161's functions and mechanisms offers a promising avenue for developing novel therapeutic approaches to combat this and potentially other Shh signaling-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.